We present the management of the second reported case of carcinosarcoma of the kidney parenchyma with malignant degeneration of both epithelial and mesenchymal components.
-
2020 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
We present the management of the second reported case of carcinosarcoma of the kidney parenchyma with malignant degeneration of both epithelial and mesenchymal components.
Uploaded on: February 14, 2024 -
2018 (v1)Publication
Background: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival outcomes. Methods: This was a retrospective...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2019 (v1)Publication
: Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of reliable biomarkers to non-invasively determine its efficacy (possibly improving patients'...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2024 (v1)Publication
: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive...
Uploaded on: July 3, 2024